Skip to main content

Table 3 Survival analyses comparing the risk of all-cause and cause-specific mortality between the study groups

From: The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records

 

Unadjusted

Age-sex adjusted

Propensity score-weighted

All-cause mortality, hazard ratios (95% CI)a

 Time < 2 years from starting treatment

  Mirtazapine/SSRI

3.19 (2.56–3.97)

1.58 (1.27–1.97)

1.62 (1.28–2.06)

  Mirtazapine/amitriptyline

1.35 (1.04–1.75)

1.12 (0.86–1.45)

1.18 (0.85–1.63)

  Mirtazapine/venlafaxine

3.10 (1.92–4.99)

1.26 (0.78–2.03)

1.11 (0.60–2.05)

 Time 2+ years from starting treatment

  Mirtazapine/SSRI

2.68 (1.92–3.75)

1.26 (0.90–1.76)

1.51 (1.04–2.19)

  Mirtazapine/amitriptyline

2.28 (1.34–3.87)

2.01 (1.18–3.41)

2.59 (1.38–4.86)

  Mirtazapine/venlafaxine

3.64 (1.80–7.35)

1.33 (0.66–2.70)

2.35 (1.02–5.44)

Deaths due to diseases of the circulatory system, subdistribution hazard ratios (95% CI)

 Mirtazapine/SSRI

2.42 (1.70–3.46)

1.10 (0.76–1.58)

1.41 (0.96–2.08)

 Mirtazapine/amitriptyline

1.35 (0.85–2.16)

1.04 (0.64–1.67)

1.11 (0.65–1.88)

 Mirtazapine/venlafaxine

3.07 (1.39–6.77)

1.09 (0.49–2.43)

0.74 (0.27–2.01)

Deaths due to diseases of the respiratory system, subdistribution hazard ratios (95% CI)

 Mirtazapine/SSRI

2.86 (1.86–4.42)

1.24 (0.80–1.94)

1.72 (1.07–2.77)

 Mirtazapine/amitriptyline

1.60 (0.90–2.84)

1.21 (0.68–2.14)

1.40 (0.73–2.68)

 Mirtazapine/venlafaxine

2.24 (1.00–5.03)

0.73 (0.34–1.55)

1.53 (0.62–3.75)

Deaths due to neoplasms, subdistribution hazard ratios (95% CI)a

 Time < 2 years from starting treatment

  Mirtazapine/SSRI

3.82 (2.44–5.98)

2.08 (1.32–3.29)

1.74 (1.06–2.85)

  Mirtazapine/amitriptyline

0.86 (0.55–1.34)

0.74 (0.47–1.16)

1.08 (0.64–1.81)

  Mirtazapine/venlafaxine

2.46 (1.04–5.78)

1.19 (0.50–2.84)

1.14 (0.42–3.09)

 Time 2+ years from starting treatment

  Mirtazapine/SSRI

2.82 (1.42–5.60)

1.44 (0.72–2.88)

1.86 (0.89–3.89)

  Mirtazapine/amitriptyline

9.90 (1.29–75.84)

8.21 (1.06–63.35)

9.37 (1.20–73.29)

  Mirtazapine/venlafaxine

3.94 (0.90–17.36)

1.74 (0.39–7.78)

4.79 (1.00–22.99)

  1. Cox regression was performed for all-cause mortality and Fine-Gray (competing risk) regression for cause-specific mortality
  2. CI confidence interval, SSRI selective serotonin reuptake inhibitor
  3. aModel includes interaction between the study group and follow-up time, split at time = 2 years
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us